Dasatinib, an immunomodulator?

Abstract

In this issue of Blood, Kreutzman and colleagues describe the existence of clonal cytotoxic T and NK cells in over 80% (15 of 18) of patients with CML at diagnosis which persisted during treatment with the tyrosine kinase inhibitors, imatinib and dasatinib.1 Furthermore, they discovered that this clonal lymphocytosis expands further after therapy with dasatinib but not imatinib.